MARINUS PHARMACEUTICALS INC (MRNS)
US56854Q2003 - Common Stock
We assign a fundamental rating of 2 out of 10 to MRNS. MRNS was compared to 198 industry peers in the Pharmaceuticals industry. MRNS may be in some trouble as it scores bad on both profitability and health. MRNS shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
MRNS had negative earnings in the past year.
MRNS had a negative operating cash flow in the past year.
In the past 5 years MRNS always reported negative net income.
MRNS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
MRNS's Return On Assets of -82.73% is on the low side compared to the rest of the industry. MRNS is outperformed by 74.87% of its industry peers.
With a Return On Equity value of -843.42%, MRNS is not doing good in the industry: 85.64% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -82.73% | ||
| ROE | -843.42% | ||
| ROIC | N/A |
ROA(3y)-54.19%
ROA(5y)-53.62%
ROE(3y)-348.39%
ROE(5y)-232.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MRNS has a better Gross Margin (93.75%) than 95.90% of its industry peers.
MRNS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.75% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MRNS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRNS has more shares outstanding
MRNS has more shares outstanding than it did 5 years ago.
MRNS has a worse debt/assets ratio than last year.
2.2 Solvency
MRNS has an Altman-Z score of -5.85. This is a bad value and indicates that MRNS is not financially healthy and even has some risk of bankruptcy.
MRNS has a worse Altman-Z score (-5.85) than 66.67% of its industry peers.
A Debt/Equity ratio of 3.66 is on the high side and indicates that MRNS has dependencies on debt financing.
MRNS has a worse Debt to Equity ratio (3.66) than 85.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.66 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.85 |
ROIC/WACCN/A
WACC10.76%
2.3 Liquidity
MRNS has a Current Ratio of 4.07. This indicates that MRNS is financially healthy and has no problem in meeting its short term obligations.
MRNS has a Current ratio of 4.07. This is comparable to the rest of the industry: MRNS outperforms 57.95% of its industry peers.
A Quick Ratio of 4.01 indicates that MRNS has no problem at all paying its short term obligations.
The Quick ratio of MRNS (4.01) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.07 | ||
| Quick Ratio | 4.01 |
3. Growth
3.1 Past
MRNS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.82%, which is quite good.
MRNS shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.62%.
Measured over the past years, MRNS shows a very strong growth in Revenue. The Revenue has been growing by 162.16% on average per year.
EPS 1Y (TTM)19.82%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q2.63%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y162.16%
Revenue growth 5YN/A
Revenue growth Q2Q0.42%
3.2 Future
Based on estimates for the next years, MRNS will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.38% on average per year.
MRNS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 70.08% yearly.
EPS Next Y8.34%
EPS Next 2Y12.84%
EPS Next 3Y18.03%
EPS Next 5Y19.38%
Revenue Next Year27.41%
Revenue Next 2Y44.72%
Revenue Next 3Y70.55%
Revenue Next 5Y70.08%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
MRNS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MRNS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MRNS's earnings are expected to grow with 18.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.84%
EPS Next 3Y18.03%
5. Dividend
5.1 Amount
No dividends for MRNS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MARINUS PHARMACEUTICALS INC
NASDAQ:MRNS (5/2/2024, 6:07:28 PM)
After market: 1.47 +0.02 (+1.38%)1.45
-0.02 (-1.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap79.65M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -82.73% | ||
| ROE | -843.42% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.75% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.66 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.07 | ||
| Quick Ratio | 4.01 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)19.82%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y8.34%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)21.62%
Revenue growth 3Y162.16%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y